ClinicalTrials.gg
CompletedNCT04202965Updated Aug 20, 2025Results posted

PTG-300 in Subjects With Hereditary Hemochromatosis

A Phase 2 interventional study of PTG-300 in Hereditary Hemochromatosis, sponsored by Protagonist Therapeutics, Inc.. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Protagonist Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Hemochromatosis with a site in United States — none open to participants now, 2 under way, none of them phase 3. Hemochromatosis · United States.

Started
2020
the only one that year
Phase 2
4 of 16
none open now
Registered
14th of 16
by date

Among the 16 studies in Hemochromatosis with a site in United States, this one is the only one that started in 2020, is one of 4 in phase 2, and was the 14th registered.

Hemochromatosis

55 studies on the registry are indexed under Hemochromatosis; 4 are open to participants now.

Browse Hemochromatosis studies →

Open to participants now

None of the 16 studies in Hemochromatosis with a site in United States is open now. The open studies under Hemochromatosis, anywhere →

Who these studies take

Of the 4 Hemochromatosis studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Hemochromatosis with a site in United States as a file.
02

Study summary

This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.

Read the detailed description

This study is a multicenter, open-label study. The objective of the study is to assess the effect of PTG-300 on transferrin saturation (TSAT) and serum iron in adult hereditary hemochromatosis patients.

03

Conditions studied

  • Hereditary Hemochromatosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 and older
  • Confirmed diagnosis of HFE-related hereditary hemochromatosis with prior genotype testing
  • Documented stable phlebotomy for ≥ 6 months
  • Screening >11.5 g/dL
  • Documented evidence of prior serum ferritin ≥500 ng/mL
  • Serum ferritin >50 ng/mL and \<300 ng/mL at screening

Exclusion criteria

Exclusion Criteria:

  • laboratory abnormality
  • Receiving iron chelation therapy
  • Receiving erythrocytapheresis
  • Pregnant or lactating females
  • Infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection within 3 months of dosing; any infections requiring antimicrobial therapy within 4 weeks of dosing.
  • Serious or unstable medical or psychiatric condition that would prevent subject providing
  • Organ damage from iron overload
  • Primary or secondary immunodeficiency
  • Positive or or known infection
  • Known history of /inflammatory diseases
  • Any surgical procedures requiring general anesthesia within 1 month prior to screening or planned surgery during study
  • History of invasive within last 2 years, except non-malignant skin cancer and local cured prostate cancer, cervical cancer, or ductal carcinoma in situ
  • Receipt of an agent within 30 days of screening
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    PTG-300

    PTG-300 Subcutaneous

    Drug: PTG-300

Interventions

  • Active treatment with PTG-300 injected subcutaneously.

    Also known as: Rusfertide

06

What researchers measure

Primary outcomes

  1. Effect of PTG-300 on Transferrin Saturation

    Change from Baseline to Week 24 (or End of Treatment) in transferrin saturation (TSAT) as measured by blood laboratory tests.

    Time frame: Week 24 (or End of Treatment if treated for less than 24 weeks)

  2. Effect of PTG-300 on Serum Iron

    Change from Baseline to Week 24 (or End of Treatment) in serum iron as measured by blood laboratory tests.

    Time frame: Week 24 (or End of Treatment if treated for less than 24 weeks)

Secondary outcomes

  1. Effect of PTG-300 on Phlebotomy Frequency

    Change in number of phlebotomies in 24-weeks before treatment compared with the number of phlebotomies during 24-weeks of treatment with PTG-300.

    Time frame: Over 24 weeks

Other outcomes

  1. Mental Component Summary of SF-36

    Change from Baseline to Week 24 (or End of Treatment) in Mental Component Summary of the SF-36. The SF-36 is a questionnaire of health status based on 36 questions distributed into eight domains of daily life that are frequently evaluated as influenced by disease. Values in each domain range from 0 to 100, with higher scores indicating better health condition. A summary measure, Mental Component Summary (MCS), for mental health can be calculated. The MCS ranges from 0 (low functioning) to 100 (high functioning).

    Time frame: Week 24 (or End of Treatment if treated for less than 24 weeks)

  2. Physical Component Summary of SF-36

    Change from Baseline to Week 24 (or End of Treatment) in Physical Component Summary of the SF-36. The SF-36 is a questionnaire of health status based on 36 questions distributed into eight domains of daily life that are frequently evaluated as influenced by disease. Values in each domain range from 0 to 100, with higher scores indicating better health condition. A summary measure, Physical Component Summary (PCS), for mental health can be calculated. The PCS ranges from 0 (low functioning) to 100 (high functioning).

    Time frame: Week 24 (or End of Treatment if treated for less than 24 weeks)

07

Results

Posted Jun 15, 2023

Participant flow

Participant flow — Overall Study
MilestonePTG-300
Started16
Completed12
Not completed4
Withdrew: Adverse event3
Withdrew: Did not meet inclusion criteria1

Outcome measures

PrimaryEffect of PTG-300 on Transferrin Saturation

Change from Baseline to Week 24 (or End of Treatment) in transferrin saturation (TSAT) as measured by blood laboratory tests.

Time frame:
Week 24 (or End of Treatment if treated for less than 24 weeks)
Reported as:
Mean · percent saturation
Effect of PTG-300 on Transferrin Saturation
percent saturationPTG-300
Effect of PTG-300 on Transferrin Saturation-6.07 ± 19.4
PrimaryEffect of PTG-300 on Serum Iron

Change from Baseline to Week 24 (or End of Treatment) in serum iron as measured by blood laboratory tests.

Time frame:
Week 24 (or End of Treatment if treated for less than 24 weeks)
Reported as:
Mean · micromol/L
Effect of PTG-300 on Serum Iron
micromol/LPTG-300
Effect of PTG-300 on Serum Iron-2.34 ± 9.76
SecondaryEffect of PTG-300 on Phlebotomy Frequency

Change in number of phlebotomies in 24-weeks before treatment compared with the number of phlebotomies during 24-weeks of treatment with PTG-300.

Time frame:
Over 24 weeks
Reported as:
Mean · phlebotomies/week
Effect of PTG-300 on Phlebotomy Frequency
phlebotomies/weekPTG-300
Effect of PTG-300 on Phlebotomy Frequency0.00 ± 0.01
Other pre-specifiedMental Component Summary of SF-36

Change from Baseline to Week 24 (or End of Treatment) in Mental Component Summary of the SF-36. The SF-36 is a questionnaire of health status based on 36 questions distributed into eight domains of daily life that are frequently evaluated as influenced by disease. Values in each domain range from 0 to 100, with higher scores indicating better health condition. A summary measure, Mental Component Summary (MCS), for mental health can be calculated. The MCS ranges from 0 (low functioning) to 100 (high functioning).

Time frame:
Week 24 (or End of Treatment if treated for less than 24 weeks)
Reported as:
Mean · units on a scale
Mental Component Summary of SF-36
units on a scalePTG-300
Mental Component Summary of SF-36-0.251 ± 9.379
Other pre-specifiedPhysical Component Summary of SF-36

Change from Baseline to Week 24 (or End of Treatment) in Physical Component Summary of the SF-36. The SF-36 is a questionnaire of health status based on 36 questions distributed into eight domains of daily life that are frequently evaluated as influenced by disease. Values in each domain range from 0 to 100, with higher scores indicating better health condition. A summary measure, Physical Component Summary (PCS), for mental health can be calculated. The PCS ranges from 0 (low functioning) to 100 (high functioning).

Time frame:
Week 24 (or End of Treatment if treated for less than 24 weeks)
Reported as:
Mean · units on a scake
Physical Component Summary of SF-36
units on a scakePTG-300
Physical Component Summary of SF-362.263 ± 6.528

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PTG-3000/16 (0%)1/16 (6.3%)12/16 (75%)
Most frequent serious events
Most frequent serious events
EventPTG-300
Adenocarcinoma pancreasNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/16
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPTG-300
Injection site painGeneral disorders5/16
Injection site pruritusGeneral disorders3/16
DiarrheaGastrointestinal disorders2/16
FatigueGeneral disorders2/16
Injection site erythemaGeneral disorders2/16
DizzinessNervous system disorders2/16
HeadacheNervous system disorders2/16
HypertensionVascular disorders2/16
Dry mouthGastrointestinal disorders1/16
NauseaGastrointestinal disorders1/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)PTG-300
Mean62.5 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)PTG-300
Female6
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PTG-300
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PTG-300
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White15
More than one race0
Unknown or Not Reported1
BMI
BMI(kg/m^2)PTG-300
Mean28.0 ± 3.87
08

Study locations

11 sites
  • Protagonist Investigational Site
    Fayetteville, Georgia 30214, United States
  • Protagonist Investigational Site
    Bethesda, Maryland 20817, United States
  • Protagonist Investigational Site
    Charlotte, North Carolina 28210, United States
  • Protagonist Investigational Site
    Conroe, Texas 77384, United States
  • Protagonist Investigational Site
    Dallas, Texas 75246, United States
  • Protagonist Investigational Site
    Houston, Texas 77030, United States
  • Protagonist Investigational Site
    Houston, Texas 77058, United States
  • Protagonist Investigational Site
    Richmond, Virginia 23226, United States
  • Protagonist Investigational Site
    Seattle, Washington 98105, United States
  • Protagonist Investigational Site
    Halifax, Nova Scotia, Canada
  • Protagonist Investigational Site
    Toronto, Ontario M6H 3M1, Canada
09

References and documents

Publications

  • Kowdley KV, Modi NB, Peltekian K, Vierling JM, Ferris C, Valone FH, Gupta S. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1118-1128. doi: 10.1016/S2468-1253(23)00250-9. Epub 2023 Oct 17. PubMed 37863080 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Oct 2021, 18 months.

Results were first posted in Jun 2023, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2019
First posted
Dec 18, 2019
StartActual
Mar 19, 2020
Primary completionActual
Oct 6, 2021
CompletionActual
Feb 15, 2022
Results first posted
Jun 15, 2023
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04202965
Lead sponsor
Protagonist Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 18, 2019
Start date
Mar 19, 2020
Primary completion
Oct 6, 2021
Completion
Feb 15, 2022
Results posted
Jun 15, 2023
Last update
Aug 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rusfertide

Start the discussion